However, the development of FDA methodology for longitudinal data, with relatively small numbers of measurements per subject and irregularly spaced, is an area of ongoing research [40], and has been used to model trajectories of prostate specific antigen (a biomarker of prostate cancer) [41,42]. The gene discussed is KLK3; the disease is prostate cancer.